Pharmaceutical pricing, cost containment and new treatments for rare diseases in children

Cost-containment in healthcare spending has become a central issue in public policy and healthcare reform, especially as the affordable care act adds millions of people to public and private insurance rolls. In this climate, longstanding criticism of pharmaceutical pricing has grown sharper, and man...

Descripción completa

Detalles Bibliográficos
Autores principales: Stella, Peter, Gold-von Simson, Gabrielle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Position Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221662/
https://www.ncbi.nlm.nih.gov/pubmed/25348640
http://dx.doi.org/10.1186/s13023-014-0152-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221662/
https://www.ncbi.nlm.nih.gov/pubmed/25348640
http://dx.doi.org/10.1186/s13023-014-0152-2

Ejemplares similares